menu
    • menu

    Company profile for Avidity Biosciences

    NEW Drugs in Dev: 8
    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Avidity Biosciences is a privately-held biotech company pioneering Antibody Oligonucleotide Conjugates (AOC™). AOCs combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapeutics to overcome barriers to the delivery of oligonucleotides and target genetic drivers of disease

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Avidity BiosciencesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    10975 N. Torrey Pines Rd. Suite 150 La Jolla, CA 92037
    Telephone
    Telephone
    858-401-7900
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.aviditybiosciences.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/avidity-biosciences-llc
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASPEN

    ASPEN

    Not Confirmed

    envelop Contact Supplier

    ASPEN

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sarepta Challenges Prompt Search For Advancements In DMD Therapy
    Sarepta Challenges Prompt Search For Advancements In DMD Therapy

    09 Feb 2026

    // BIOSPACE

    https://www.biospace.com/drug-development/following-sarepta-woes-others-look-to-unlock-the-next-chapter-in-dmd-treatment

    BIOSPACE
    09 Feb 2026
    Share Share
    Avidity Biosciences Launches U.S. Managed Access Program
    Avidity Biosciences Launches U.S. Managed Access Program

    19 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/avidity-biosciences-announces-us-managed-access-program-map-for-investigational-therapy-del-zota-in-dmd44-302620325.html

    PR NEWSWIRE
    19 Nov 2025
    Share Share
    Avidity Biosciences Unveils Q3 2025 Financials & Highlights
    Avidity Biosciences Unveils Q3 2025 Financials & Highlights

    11 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/avidity-biosciences-reports-third-quarter-2025-financial-results-and-recent-highlights-302610417.html

    PR NEWSWIRE
    11 Nov 2025
    Share Share
    Novartis Bolsters Neuromuscular Pipeline Via $12B Avidity Buyout
    Novartis Bolsters Neuromuscular Pipeline Via $12B Avidity Buyout

    27 Oct 2025

    // BIOSPACE

    https://www.biospace.com/deals/novartis-to-bolster-neuromuscular-pipeline-with-12b-avidity-acquisition

    BIOSPACE
    27 Oct 2025
    Share Share
    Avidity Biosciences Joins Investor Conference
    Avidity Biosciences Joins Investor Conference

    16 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conference-302585667.html

    PR NEWSWIRE
    16 Oct 2025
    Share Share
    Avidity Biosciences Plans Del-Zota Bla Submission For DMD44
    Avidity Biosciences Plans Del-Zota Bla Submission For DMD44

    13 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/avidity-biosciences-announces-positive-pre-bla-meeting-with-us-fda-for-del-zota-in-dmd44-with-a-submission-planned-for-q1-2026-302581552.html

    PR NEWSWIRE
    13 Oct 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search